GSC
ARTV

Ground Swell Capital’s Artiva Biotherapeutics ARTV Stock Holding History

Ground Swell Capital’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,849
Closed -$37.5K – 254
2025
Q2 		$37.5K Buy
+24,849
New +$52.2K 0.06% 77

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ground Swell Capital's ARTV Position: Q3 2025 in Review

Ground Swell Capital sold out of Artiva Biotherapeutics (ARTV) in Q3 2025, closing a stake of 24,849 shares — an estimated $37.5K sold.

Ground Swell Capital first reported a position in ARTV in Q2 2025 and held it in 1 quarter. The position peaked at $37.5K in Q2 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q3 2025.

  • Ground Swell Capital reported no remaining Artiva Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Ground Swell Capital sold 24,849 Artiva Biotherapeutics shares in Q3 2025, an estimated $37.5K.
  • Ground Swell Capital first reported a position in Artiva Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • Ground Swell Capital's Artiva Biotherapeutics position peaked at $37.5K in Q2 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2025.

Based on Ground Swell Capital's 13F filing for Q3 2025, filed 6 Nov 2025.